Vibha Jawa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5488965/publications.pdf

Version: 2024-02-01

23	1,162	759233 12	677142 22
papers	citations	h-index	g-index

24	24	24	1281
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays. MAbs, 2022, 14, 1993522.	5.2	25
2	Holistic Analytical Characterization and Risk Assessment of Residual Host Cell Protein Impurities in an Active Pharmaceutical Ingredient (API) Synthesized by Biocatalysts. Biotechnology and Bioengineering, 2022, , .	3.3	2
3	The Impact of Product and Process Related Critical Quality Attributes on Immunogenicity and Adverse Immunological Effects of Biotherapeutics. Journal of Pharmaceutical Sciences, 2021, 110, 1025-1041.	3.3	15
4	Failure Mode and Effects Analysis (FMEA) for Immunogenicity of Therapeutic Proteins. Journal of Pharmaceutical Sciences, 2020, 109, 3214-3222.	3.3	2
5	Assessment of romiplostim immunogenicity in adult patients in clinical trials and in a global postmarketing registry. British Journal of Haematology, 2020, 190, 923-932.	2.5	12
6	Immune Suppression During Preclinical Drug Development Mitigates Immunogenicity-Mediated Impact on Therapeutic Exposure. AAPS Journal, 2017, 19, 447-455.	4.4	5
7	A Proposal to Redefine Clinical Immunogenicity Assessment. AAPS Journal, 2017, 19, 599-602.	4.4	8
8	How Close Are We to Profiling Immunogenicity Risk Using In Silico Algorithms and In Vitro Methods?: an Industry Perspective. AAPS Journal, 2017, 19, 1587-1592.	4.4	33
9	Assay signal as an alternative to titer for assessment of magnitude of an antidrug antibody response. Bioanalysis, 2017, 9, 1849-1858.	1.5	12
10	Chemical and Biophysical Characteristics of Monoclonal Antibody Solutions Containing Aggregates Formed during Metal Catalyzed Oxidation. Pharmaceutical Research, 2017, 34, 2817-2828.	3.5	12
11	Use of In Vitro Assays to Assess Immunogenicity Risk of Antibody-Based Biotherapeutics. PLoS ONE, 2016, 11, e0159328.	2.5	89
12	Mouse Models for Assessing Protein Immunogenicity: Lessons and Challenges. Journal of Pharmaceutical Sciences, 2016, 105, 1567-1575.	3.3	88
13	Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics. AAPS Journal, 2016, 18, 1439-1452.	4.4	58
14	Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins. AAPS Journal, 2016, 18, 424-431.	4.4	9
15	Impact of Anti-Drug Antibodies in Preclinical Pharmacokinetic Assessment. AAPS Journal, 2013, 15, 856-863.	4.4	35
16	T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clinical Immunology, 2013, 149, 534-555.	3.2	216
17	Highly Aggregated Antibody Therapeutics Can Enhance the in Vitro Innate and Late-stage T-cell Immune Responses. Journal of Biological Chemistry, 2012, 287, 25266-25279.	3.4	224
18	Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy. AAPS Journal, 2012, 14, 296-302.	4.4	262

#	Article	IF	Citations
19	Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects. Annals of Hematology, 2010, 89, 75-85.	1.8	28
20	Impact Assessment of Immunogenicity of Romiplostim In Subjects with Immune Thrombocytopenic Purpura (ITP). Blood, 2010, 116, 2517-2517.	1.4	5
21	Elimination of rheumatoid factor interference in immunoassays using the electrochemiluminescence (ECL) based Meso Scale Discovery (MSD) platform. FASEB Journal, 2008, 22, 566-566.	0.5	2
22	Low Immunogenicity to Romiplostim in Clinical Studies with ITP Subjects.. Blood, 2008, 112, 3425-3425.	1.4	18
23	Correlation of in silico prediction of immunogenicity of therapeutic proteins with immune responses in clinical studies.. FASEB Journal, 2008, 22, 563-563.	0.5	0